Tien Liang BioTech Co., Ltd. (4127.TWO)

Tien Liang BioTech Co., Ltd. (4127.TWO) — VMCI valuation read

Tien Liang BioTech Co., Ltd. sits at VMCI 37/100, with the Healthcare sector median at 50. That 13-point spread is the first thing to note on 4127.TWO: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on 4127.TWO are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on 4127.TWO: 4127.TWO trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 2.2x is the rate-sensitivity line to watch, anchoring the bear scenario on a measurable balance-sheet metric.

4127.TWO rose 4.0% over the trailing 7 days, with a +5.2% read on a 30-day basis.